emergentec biodevelopment was founded in 2002 by a team of researchers from molecular biology and computer science. We provide innovative concepts and computational solutions for adding essence to informed decision making in biomarker, target and drug development.
We focus on an integrative, big data concept: Molecular annotation and models serving as composite of the molecular process landscape characterizing the pathophysiology of clinical phenotypes. We on this basis evaluate biomarkers (as proxies for the molecular process landscape), drug targets (for addressing relevant aspects of the molecular pathophysiology), and drug Mechanism of Action (for matching disease pathophysiology and a drug's molecular effect).
Our lead platform e.valuation embeds fit-for-purpose analysis workflows for biomarker, target and drug assets - adding precision from translational research to clinical development.
>> read more about how e.valuation improves R&D productivity.